<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15413">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00157157</url>
  </required_header>
  <id_info>
    <org_study_id>060103</org_study_id>
    <nct_id>NCT00157157</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients</brief_title>
  <official_title>Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta US Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baxalta US Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <authority>Austria: Federal Ministry for Health and Women</authority>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>Italy: Ministry of Health</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <authority>Sweden: Medical Products Agency</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether Antihemophilic factor, recombinant,
      manufactured protein-free (rAHF-PFM) is effective and safe in the treatment of hemophilia A
      patients who have not been treated with factor VIII (FVIII) before.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Factor VIII Inhibitor Development</measure>
    <time_frame>Assessed during study period which was to be at least 75 exposure days or 3 years (whichever came first)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Percentage of treated participants who developed factor VIII inhibitors</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding Episodes Treated With 1 to ≥4 Infusions</measure>
    <time_frame>Reported during study period which was to be at least 75 exposure days or 3 years (whichever came first)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of bleeding episodes treated with 1, 2, 3, or ≥4 infusions of rAHF-PFM to achieve adequate hemostasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Hemostasis for Treatment of Bleeding Episodes</measure>
    <time_frame>Reported during study period which was to be at least 75 exposure days or 3 years (whichever came first)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of rAHF-PFM-treated bleeding episodes with treater assessment of hemostasis (4-point ordinal scale):
Excellent: Full pain relief &amp; bleeding cessation within ~8 hrs of 1 infusion. Additional infusions may have been given to maintain hemostasis;
Good: Definite pain relief and/or improvement in bleeding within ~8 hrs after infusion. Possibly requires &gt;1 infusion for complete resolution;
Fair: Probable or slight relief of pain &amp; slight improvement in bleeding within ~8 hrs after infusion. Requires &gt;1 infusion for complete resolution; or
None: No improvement or condition worsens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized Rate of Bleeding Episodes</measure>
    <time_frame>Reported during study period which was to be at least 75 exposure days or 3 years (whichever came first)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of bleeding episodes per subject annualized over 1 year for all etiologies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly rAHF-PFM Utilization</measure>
    <time_frame>Reported during study period which was to be at least 75 exposure days or 3 years (whichever came first)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Weight-Adjusted Weekly Dose for Prophylaxis, On-Demand Treatment, and Perioperative Management.
rAHF-PFM dose determined by the investigator (ie: standard regimen [25-50 IU/kg body weight, 3-4 times per week]; modified prophylactic regimen [dose and frequency selected by investigator] or on-demand treatment [dose selected by investigator]). Dosing to treat BEs was at investigator's discretion and in accordance with institution's standard of care.
rAHF-PFM was administered I.V. via bolus infusion, except for perioperative management when it was given either by continuous or bolus infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In Vivo Incremental Recovery</measure>
    <time_frame>30 minutes pre-infusion to 30 minutes post-infusion</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in factor VIII concentration from pre- to post-infusion at initial and termination study visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Intra-operative Hemostasis</measure>
    <time_frame>Assessed at the time of discharge from recovery room</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of surgical procedures managed with rAHF-PFM and with surgeon's assessment of hemostasis based on a 4-point ordinal scale:
Excellent: ≤ average predicted blood loss for matched procedures in healthy individuals
Good: &gt; average predicted blood loss, but ≤ maximal predicted blood loss for matched procedures in healthy individuals
Fair: &gt; maximal predicted blood loss for matched procedures in healthy individuals, and hemostasis was achieved
None: uncontrolled hemostasis with proper dosing, necessitating a change in treatment regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Postoperative Hemostasis</measure>
    <time_frame>Assessed at the time of discharge from hospital or clinic</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of surgical procedures managed with rAHF-PFM and with investigator's assessment of hemostasis based on a 4-point ordinal scale:
Excellent: hemostasis was as good as or better than other licensed factor VIII products for matched procedure
Good: hemostasis was probably as good as other licensed factor VIII products for matched procedure
Fair: hemostasis was clearly &lt; optimal for matched procedure, without need to change regimen
None: bleeding from inadequate response with proper dosing, necessitating a change in regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Blood Loss During Surgical Procedures</measure>
    <time_frame>Predicted volumes preoperatively estimated and actual volumes intraoperatively recorded</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of actual intraoperative blood loss compared to preoperatively predicted average and maximal blood loss in hemostatically normal matched individuals (from institutional blood bank records)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events Deemed Related to Treatment</measure>
    <time_frame>Reported during the study period which was to be at least 75 exposure days or 3 years (whichever came first)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Percentage of participants who reported AEs deemed related to treatment with rAHF-PFM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Antibodies to Heterologous Proteins</measure>
    <time_frame>Assessed at baseline, throughout the duration of the study, which was to be at least 75 exposure days or 3 years (whichever came first), and at the termination visit.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Percentage of treated participants who developed antibodies to heterologous proteins (ie, Chinese Hamster Ovary Cell Protein, Murine IgG, or Recombinant Human VWF)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Single Arm - All Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)</intervention_name>
    <description>Treatment regimens were determined by the investigator, and may have been any combination of standard prophylaxis (25 to 50 IU/kg body weight, 3 to 4 times per week), investigator-determined prophylaxis, and/or on-demand treatment (dose selected by investigator).
The treatment of bleeding episodes and perioperative management was at the discretion of the investigator and consistent with the institution's standard of care.
For incremental recovery assessments, a single infusion at 50 +/- 5 IU/kg was to be given.
Immune tolerance induction (ITI) therapy for subjects who developed factor VIII inhibitors was at the discretion of the investigator, based on the institution's guidelines or described in peer-reviewed literature, and was to be approved by the sponsor's medical director.
rAHF-PFM was to be administered intravenously via bolus infusion, except for perioperative management when it may have been given either by continuous or bolus infusion.</description>
    <arm_group_label>Single Arm - All Participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject has severe or moderately severe hemophilia A as defined by a baseline
             factor VIII level &lt;= 2% of normal, as documented at screening

          -  The subject is &lt; 6 years of age

          -  The subject's legally authorized representative has provided written informed consent

        Exclusion Criteria:

          -  The subject has a history of exposure to factor VIII other than rAHF PFM or more than
             3 infusions of commercially available rAHF PFM (i.e., ADVATE) within 28 days prior to
             screening, as determined by the subject's medical history. Any infusion of factor
             VIII replacement products prior to the 28-day period excludes the subject from
             participation

          -  The subject has received more than 3 infusions of rAHF PFM (commercially available
             and/or study product) between screening and prior to the initial recovery infusion

          -  The subject has a detectable inhibitor to factor VIII, as measured in the screening
             sample by the Nijmegen assay in the central laboratory

          -  The subject has a history of inhibitor to factor VIII at any time prior to screening

          -  The subject has a known hypersensitivity to rAHF PFM

          -  The subject has any 1 of the following laboratory abnormalities at the time of
             screening:

               1. Platelet count &lt; 100,000/mm^3

               2. Hemoglobin concentration &lt; 10 g/dL (100 g/L)

               3. Serum creatinine &gt; 1.5 times the upper limit of normal (ULN) for age

               4. Total bilirubin &gt; 2 times the ULN for age

          -  The subject has an inherited or acquired hemostatic defect other than hemophilia A
             (e.g., qualitative platelet defect or von Willebrand's disease)

          -  The subject is known to be seropositive for human immunodeficiency virus (HIV),
             hepatitis C virus (HCV), or hepatitis B virus (HBV), as determined by the subject's
             medical history

          -  At the time of enrollment, the subject has a clinically significant chronic disease
             other than hemophilia A

          -  The subject is currently participating in another investigational drug study, or has
             participated in any clinical study involving an investigational drug within 120 days
             of the screening visit

          -  The subject (or the subject's legally authorized representative) is identified by the
             investigator as being unable or unwilling to cooperate with study procedures

          -  The subject has received any blood product, including packed red blood cells (RBC),
             platelets, plasma, or cryoprecipitate
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baxter BioScience Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baxter BioScience</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bremen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Shapiro A, Gruppo R, Pabinger I, Collins PW, Hay CR, Schroth P, Casey K, Patrone L, Ehrlich H, Ewenstein BM. Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A. Expert Opin Biol Ther. 2009 Mar;9(3):273-83. doi: 10.1517/14712590902729392 .</citation>
    <PMID>19216617</PMID>
  </results_reference>
  <results_reference>
    <citation>Ewenstein B., Patrone L, Schroth P, Spotts G, Fritsch S, Pavlova B, Ehrlich H. Efficacy of antihemophilic factor (recombinant), plasma/albumin-free method (rAHF-PFM) in bleed prevention. J Thromb Haemost. 2007; 5(Suppl 2): P-S-179.</citation>
  </results_reference>
  <results_reference>
    <citation>Ewenstein B., Patrone L, Schroth P, Spotts G, Fritsch S, Pavlova B, Ehrlich H. Efficacy of antihemophilic factor (recombinant), plasma/albumin-free method (rAHF-PFM) in bleed treatment. J Thromb Haemost. 2007; 5(Suppl 2)v: P-S-180.</citation>
  </results_reference>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 26, 2015</lastchanged_date>
  <firstreceived_date>September 9, 2005</firstreceived_date>
  <firstreceived_results_date>February 15, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Factor VIII Deficiency</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment was conducted in the U.S., Canada, and Europe at 24 study sites.</recruitment_details>
      <pre_assignment_details>Participants screened for maximum 21 days. Study was not randomized; it was an open-label evaluation. Prior to initial infusion, a minimum washout period of 3 days was required. 11 participants who enrolled did not receive any rAHF-PFM infusions (3 withdrew consent, 6 screen failures, 1 non-compliance with screening, 1 pre-existing low hemoglobin)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Previously Untreated Patients (PUPs)</title>
          <description>rAHF-PFM was dosed according to a therapeutic regimen which was determined by the investigator (ie: standard regimen [25 to 50 IU/kg body weight, 3 to 4 times per week]; a modified prophylactic regimen [dose and frequency selected by investigator] or on–demand treatment [dose selected by investigator]). The dosing regimen used to treat bleeding episodes (BEs) was at the discretion of the investigator and in accordance with the institution’s standard of care for the type of bleeding episodes diagnosed.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Enrolled in another study</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Met exclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inclusion not met- baseline FVIII value</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PUPs</title>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="55"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;6 months</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>6-12 months</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="26"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>≥13 months</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="55"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Factor VIII Inhibitor Development</title>
        <description>Percentage of treated participants who developed factor VIII inhibitors</description>
        <time_frame>Assessed during study period which was to be at least 75 exposure days or 3 years (whichever came first)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Participants who received at least 1 infusion of rAHF-PFM</population>
        <group_list>
          <group group_id="O1">
            <title>PUPs</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="55"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Factor VIII Inhibitor Development</title>
            <description>Percentage of treated participants who developed factor VIII inhibitors</description>
            <units>percentage</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="29.1" lower_limit="17.1" upper_limit="41.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding Episodes Treated With 1 to ≥4 Infusions</title>
        <description>The number of bleeding episodes treated with 1, 2, 3, or ≥4 infusions of rAHF-PFM to achieve adequate hemostasis</description>
        <time_frame>Reported during study period which was to be at least 75 exposure days or 3 years (whichever came first)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants who received at least 1 infusion of rAHF-PFM for the treatment of bleeding episodes</population>
        <group_list>
          <group group_id="O1">
            <title>PUPs</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="44"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Bleeding Episodes Treated With 1 to ≥4 Infusions</title>
            <description>The number of bleeding episodes treated with 1, 2, 3, or ≥4 infusions of rAHF-PFM to achieve adequate hemostasis</description>
            <units>Bleeding episodes</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>1 infusion</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="356"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>2 infusions</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="107"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>3 infusions</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>4 or more infusions</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Hemostasis for Treatment of Bleeding Episodes</title>
        <description>Number of rAHF-PFM-treated bleeding episodes with treater assessment of hemostasis (4-point ordinal scale):
Excellent: Full pain relief &amp; bleeding cessation within ~8 hrs of 1 infusion. Additional infusions may have been given to maintain hemostasis;
Good: Definite pain relief and/or improvement in bleeding within ~8 hrs after infusion. Possibly requires &gt;1 infusion for complete resolution;
Fair: Probable or slight relief of pain &amp; slight improvement in bleeding within ~8 hrs after infusion. Requires &gt;1 infusion for complete resolution; or
None: No improvement or condition worsens.</description>
        <time_frame>Reported during study period which was to be at least 75 exposure days or 3 years (whichever came first)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants who received at least 1 infusion of rAHF-PFM and had at least 1 treated bleeding episode. The 1 rating of &quot;none&quot; was for the first 2 infusions, the last infusion was rated as &quot;good&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>PUPs</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="44"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Assessment of Hemostasis for Treatment of Bleeding Episodes</title>
            <description>Number of rAHF-PFM-treated bleeding episodes with treater assessment of hemostasis (4-point ordinal scale):
Excellent: Full pain relief &amp; bleeding cessation within ~8 hrs of 1 infusion. Additional infusions may have been given to maintain hemostasis;
Good: Definite pain relief and/or improvement in bleeding within ~8 hrs after infusion. Possibly requires &gt;1 infusion for complete resolution;
Fair: Probable or slight relief of pain &amp; slight improvement in bleeding within ~8 hrs after infusion. Requires &gt;1 infusion for complete resolution; or
None: No improvement or condition worsens.</description>
            <units>bleeding episodes</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Excellent</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="258"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Good</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="177"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fair</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>None</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Unknown/not assessed</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="51"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annualized Rate of Bleeding Episodes</title>
        <description>Number of bleeding episodes per subject annualized over 1 year for all etiologies</description>
        <time_frame>Reported during study period which was to be at least 75 exposure days or 3 years (whichever came first)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants treated for at least 3 months with investigator-defined on-demand treatment (for dose) or prophylaxis (for dose and infusion frequency) for &gt;80% of the treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>PUPs</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Annualized Rate of Bleeding Episodes</title>
            <description>Number of bleeding episodes per subject annualized over 1 year for all etiologies</description>
            <units>bleeding episodes per subject per year</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4.95" lower_limit="1.01" upper_limit="32.70"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weekly rAHF-PFM Utilization</title>
        <description>Weight-Adjusted Weekly Dose for Prophylaxis, On-Demand Treatment, and Perioperative Management.
rAHF-PFM dose determined by the investigator (ie: standard regimen [25-50 IU/kg body weight, 3-4 times per week]; modified prophylactic regimen [dose and frequency selected by investigator] or on–demand treatment [dose selected by investigator]). Dosing to treat BEs was at investigator's discretion and in accordance with institution’s standard of care.
rAHF-PFM was administered I.V. via bolus infusion, except for perioperative management when it was given either by continuous or bolus infusion.</description>
        <time_frame>Reported during study period which was to be at least 75 exposure days or 3 years (whichever came first)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants treated for at least 3 months with investigator-defined on-demand treatment (for dose) or prophylaxis (for dose and infusion frequency) for &gt;80% of the treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>PUPs -During Prophylaxis</title>
            <description>rAHF-PFM was dosed according to a therapeutic regimen which was determined by the investigator (ie: standard regimen [25 to 50 IU/kg body weight, 3 to 4 times per week]; a modified prophylactic regimen [dose and frequency selected by investigator]. The dosing regimen used to treat BEs was at the discretion of the investigator and in accordance with the institution’s standard of care for the type of bleeding episode (BE) diagnosed.</description>
          </group>
          <group group_id="O2">
            <title>PUPs -During On-Demand Treatment</title>
            <description>The dosing regimen used to treat BEs was at the discretion of the investigator and in accordance with the institution’s standard of care for the type of BE diagnosed.</description>
          </group>
          <group group_id="O3">
            <title>PUPs -During Perioperative Management</title>
            <description>rAHF-PFM was administered intravenously via bolus infusion, or continuous infusion. The dosing regimen used was at the discretion of the investigator and in accordance with the institution’s standard of care.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="36"/>
                  <measurement group_id="O2" value="47"/>
                  <measurement group_id="O3" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Weekly rAHF-PFM Utilization</title>
            <description>Weight-Adjusted Weekly Dose for Prophylaxis, On-Demand Treatment, and Perioperative Management.
rAHF-PFM dose determined by the investigator (ie: standard regimen [25-50 IU/kg body weight, 3-4 times per week]; modified prophylactic regimen [dose and frequency selected by investigator] or on–demand treatment [dose selected by investigator]). Dosing to treat BEs was at investigator's discretion and in accordance with institution’s standard of care.
rAHF-PFM was administered I.V. via bolus infusion, except for perioperative management when it was given either by continuous or bolus infusion.</description>
            <units>IU/kg</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="87.1" lower_limit="6.5" upper_limit="352.3"/>
                  <measurement group_id="O2" value="12.5" lower_limit="2.4" upper_limit="176.8"/>
                  <measurement group_id="O3" value="606.4" lower_limit="256.5" upper_limit="1951.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In Vivo Incremental Recovery</title>
        <description>Change in factor VIII concentration from pre- to post-infusion at initial and termination study visits.</description>
        <time_frame>30 minutes pre-infusion to 30 minutes post-infusion</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants who received pharmacokinetic rAHF-PFM infusions, did not develop inhibitors, and had assessments</population>
        <group_list>
          <group group_id="O1">
            <title>PUPs -Initial Visit</title>
            <description>Incremental recovery at the Initial Study Visit</description>
          </group>
          <group group_id="O2">
            <title>PUPs -Termination Visit</title>
            <description>Incremental recovery at the Termination Study Visit</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>In Vivo Incremental Recovery</title>
            <description>Change in factor VIII concentration from pre- to post-infusion at initial and termination study visits.</description>
            <units>IU/dL per IU/kg</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.81" lower_limit="0.74" upper_limit="1.92"/>
                  <measurement group_id="O2" value="1.71" lower_limit="1.32" upper_limit="2.11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Intra-operative Hemostasis</title>
        <description>Number of surgical procedures managed with rAHF-PFM and with surgeon's assessment of hemostasis based on a 4-point ordinal scale:
Excellent: ≤ average predicted blood loss for matched procedures in healthy individuals
Good: &gt; average predicted blood loss, but ≤ maximal predicted blood loss for matched procedures in healthy individuals
Fair: &gt; maximal predicted blood loss for matched procedures in healthy individuals, and hemostasis was achieved
None: uncontrolled hemostasis with proper dosing, necessitating a change in treatment regimen</description>
        <time_frame>Assessed at the time of discharge from recovery room</time_frame>
        <safety_issue>No</safety_issue>
        <population>Number of participants who underwent a surgical procedure with an intraoperative assessment of hemostatic efficacy</population>
        <group_list>
          <group group_id="O1">
            <title>PUPs</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Assessment of Intra-operative Hemostasis</title>
            <description>Number of surgical procedures managed with rAHF-PFM and with surgeon's assessment of hemostasis based on a 4-point ordinal scale:
Excellent: ≤ average predicted blood loss for matched procedures in healthy individuals
Good: &gt; average predicted blood loss, but ≤ maximal predicted blood loss for matched procedures in healthy individuals
Fair: &gt; maximal predicted blood loss for matched procedures in healthy individuals, and hemostasis was achieved
None: uncontrolled hemostasis with proper dosing, necessitating a change in treatment regimen</description>
            <units>Procedures</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Excellent</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Good</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Not Applicable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Not Done</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Postoperative Hemostasis</title>
        <description>Number of surgical procedures managed with rAHF-PFM and with investigator's assessment of hemostasis based on a 4-point ordinal scale:
Excellent: hemostasis was as good as or better than other licensed factor VIII products for matched procedure
Good: hemostasis was probably as good as other licensed factor VIII products for matched procedure
Fair: hemostasis was clearly &lt; optimal for matched procedure, without need to change regimen
None: bleeding from inadequate response with proper dosing, necessitating a change in regimen</description>
        <time_frame>Assessed at the time of discharge from hospital or clinic</time_frame>
        <safety_issue>No</safety_issue>
        <population>Number of participants who underwent a surgical procedure with a postoperative assessment of hemostatic efficacy</population>
        <group_list>
          <group group_id="O1">
            <title>PUPs</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Assessment of Postoperative Hemostasis</title>
            <description>Number of surgical procedures managed with rAHF-PFM and with investigator's assessment of hemostasis based on a 4-point ordinal scale:
Excellent: hemostasis was as good as or better than other licensed factor VIII products for matched procedure
Good: hemostasis was probably as good as other licensed factor VIII products for matched procedure
Fair: hemostasis was clearly &lt; optimal for matched procedure, without need to change regimen
None: bleeding from inadequate response with proper dosing, necessitating a change in regimen</description>
            <units>Procedures</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Excellent</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Good</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Not Applicable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Not Done</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Blood Loss During Surgical Procedures</title>
        <description>Percentage of actual intraoperative blood loss compared to preoperatively predicted average and maximal blood loss in hemostatically normal matched individuals (from institutional blood bank records)</description>
        <time_frame>Predicted volumes preoperatively estimated and actual volumes intraoperatively recorded</time_frame>
        <safety_issue>No</safety_issue>
        <population>Number of participants who underwent a surgical procedure with blood loss assessments</population>
        <group_list>
          <group group_id="O1">
            <title>PUPs</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Assessment of Blood Loss During Surgical Procedures</title>
            <description>Percentage of actual intraoperative blood loss compared to preoperatively predicted average and maximal blood loss in hemostatically normal matched individuals (from institutional blood bank records)</description>
            <units>Percentage Blood Loss</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <sub_title>Blood loss as percentage of predicted average</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50.0" lower_limit="0.0" upper_limit="250"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Blood loss as percentage of predicted maximal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20.0" lower_limit="0.0" upper_limit="100.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events Deemed Related to Treatment</title>
        <description>Percentage of participants who reported AEs deemed related to treatment with rAHF-PFM</description>
        <time_frame>Reported during the study period which was to be at least 75 exposure days or 3 years (whichever came first)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Participants who received at least 1 infusion of rAHF-PFM</population>
        <group_list>
          <group group_id="O1">
            <title>PUPs</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="55"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Adverse Events Deemed Related to Treatment</title>
            <description>Percentage of participants who reported AEs deemed related to treatment with rAHF-PFM</description>
            <units>Percentage of Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="36.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Development of Antibodies to Heterologous Proteins</title>
        <description>Percentage of treated participants who developed antibodies to heterologous proteins (ie, Chinese Hamster Ovary Cell Protein, Murine IgG, or Recombinant Human VWF)</description>
        <time_frame>Assessed at baseline, throughout the duration of the study, which was to be at least 75 exposure days or 3 years (whichever came first), and at the termination visit.</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Participants who received at least 1 infusion of rAHF-PFM and had assessments of heterologous antibodies</population>
        <group_list>
          <group group_id="O1">
            <title>PUPs</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="55"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Development of Antibodies to Heterologous Proteins</title>
            <description>Percentage of treated participants who developed antibodies to heterologous proteins (ie, Chinese Hamster Ovary Cell Protein, Murine IgG, or Recombinant Human VWF)</description>
            <units>Percentage of Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Antibodies to Chinese Hamster Ovary Cell Protein</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.00"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Antibodies to Murine IgG</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.00"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Antibodies to Recombinant Human VWF (n=54)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.00"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Factor VIII Inhibitor Risk Factor: Genetic Risk Factor- Family History of Inhibitors</title>
        <description>Number of treated participants who developed an inhibitor</description>
        <time_frame>Duration of study which was to be at least 75 exposure days or 3 years (whichever came first)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Immunogenicity Analysis Set- Participants who developed an inhibitor or who were inhibitor-free with ≥10 exposure days to rAHF-PFM</population>
        <group_list>
          <group group_id="O1">
            <title>PUPs - Did Not Develop Factor VIII Inhibitor</title>
          </group>
          <group group_id="O2">
            <title>PUPs - Developed Factor VIII Inhibitor</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Factor VIII Inhibitor Risk Factor: Genetic Risk Factor- Family History of Inhibitors</title>
            <description>Number of treated participants who developed an inhibitor</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Has Family History of Inhibitors</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Unknown Family History of Inhibitors</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>No Family History of Inhibitors</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.29</ci_lower_limit>
            <ci_upper_limit>19.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Factor VIII Inhibitor Risk Factor: Race</title>
        <description>Number of treated participants who developed an inhibitor</description>
        <time_frame>Duration of study which was to be at least 75 exposure days or 3 years (whichever came first)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Immunogenicity Analysis Set- Participants who developed an inhibitor or who were inhibitor-free with ≥10 exposure days to rAHF-PFM</population>
        <group_list>
          <group group_id="O1">
            <title>PUPs - Did Not Develop Factor VIII Inhibitor</title>
          </group>
          <group group_id="O2">
            <title>PUPs - Developed Factor VIII Inhibitor</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Factor VIII Inhibitor Risk Factor: Race</title>
            <description>Number of treated participants who developed an inhibitor</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Non-Caucasian</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Caucasian</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.18</ci_lower_limit>
            <ci_upper_limit>14.82</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Factor VIII Inhibitor Risk Factor: Number of Participants With Intensive Treatment and High Dose (≤20 Exposure Days (EDs))</title>
        <description>Immunogenicity Analysis Set- Participants with 5 consecutive study days of a mean infusion dose of FVIII &gt;50 IU/kg within ≤20 EDs who developed an inhibitor</description>
        <time_frame>Duration of study which was to be at least 75 exposure days or 3 years (whichever came first)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Immunogenicity Analysis Set- Participants who developed an inhibitor or who were inhibitor-free with ≥10 exposure days to rAHF-PFM</population>
        <group_list>
          <group group_id="O1">
            <title>PUPs - Did Not Develop Factor VIII Inhibitor</title>
          </group>
          <group group_id="O2">
            <title>PUPs - Developed Factor VIII Inhibitor</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Factor VIII Inhibitor Risk Factor: Number of Participants With Intensive Treatment and High Dose (≤20 Exposure Days (EDs))</title>
            <description>Immunogenicity Analysis Set- Participants with 5 consecutive study days of a mean infusion dose of FVIII &gt;50 IU/kg within ≤20 EDs who developed an inhibitor</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Received intensive treatment &amp; high dose</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>No intensive treatment &amp; high dose</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.05</ci_lower_limit>
            <ci_upper_limit>19.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Study period was to be at least 75 exposure days or 3 years (whichever came first)</time_frame>
      <desc>Median days on study was 498 (range: 82 to 1360) days. Median days of rAHF-PFM exposure was 76 (range: 1 to 414) exposure days.</desc>
      <group_list>
        <group group_id="E1">
          <title>PUPs</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Factor VIII inhibition</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Catheter site haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Catheter bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Mouth injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Tongue injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjuctivitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="31" subjects_affected="20" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="29" subjects_affected="17" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="137" subjects_affected="39" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="80" subjects_affected="28" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="44" subjects_affected="20" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="35" subjects_affected="16" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="13" subjects_affected="7" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hand-foot-and-mouth disease</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Gasteroenteritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Mouth injury</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="65" subjects_affected="23" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="54" subjects_affected="22" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="48" subjects_affected="15" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="18" subjects_affected="13" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Baxter's agreements with PIs vary per individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication or 1 year after study completion. Baxter requires a review of results communications (e.g., for confidential information) 30 days prior to submission or communication. Baxter may request an additional delay of up to 90 days (e.g., to allow for intellectual property protection).</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brigitt Abbuehl, MD, Medical Director, Hematology/Hemophilia</name_or_title>
      <organization>Baxter Innovations GmbH</organization>
      <email>brigitt_abbuehl@baxter.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
